Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies: Early cancers may contain aggressive genetic features

American Journal of Pathology

Volumn 158, Issue 2, 2001, Pages 399-406

  Alers, Janneke C ^a   Krijtenburg, Pieter Jaap ^a   Vis, Andre N ^a   Hoedemaeker, Robert F ^a   Wildhagen, Mark F ^a   Hop, Wim C J ^a   van der Kwast, Theodorus H ^a   Schröder, Fritz H ^a   Tanke, Hans J ^b   van Dekken, Herman ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER CYTODIAGNOSIS; CANCER SCREENING; CANCER SIZE; CHROMOSOMAL LOCALIZATION; CHROMOSOME 13Q; CHROMOSOME 6Q; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN; HUMAN TISSUE; MALE; MALE GENITAL TRACT CANCER; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE DISEASE; Y CHROMOSOME;

EID: 0035135616     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63983-1     Document Type: Article

References (49)

1. Cancer statistics, 1999
2. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: Epidemiologic significance of annual changes
3. Incidence of prostate cancer diagnosis in the eras before after serum prostate-specific antigen testing
4. Cancer surveillance series: Interpreting trend in prostate cancer-part 1: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates
5. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening
6. Early detection of prostate cancer
7. Prostate cancer diagnosis management
8. Screening for prostate cancer
9. Pathologic clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer
10. The pathological features prognosis of prostate cancer detectable with current diagnostic tests
11. Long-term survival among men with conservatively treated localized prostate cancer
12. Chromosomal clues to the development of prostate tumors
13. Allelic imbalance microsatellite instability in prostatic adenocarcinoma
14. Genetic pattern of prostate cancer progression
15. Chromosome 3p24-26 and 3p22-12 loss in human prostatic adenocarcinoma
16. Identification characterization of proximal 6q deletions in prostate cancer
17. Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression
18. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-p21
19. High frequency of deletion on chromosome 9p21 may harbor several tumor-suppressor genes in human prostate cancer
20. Loss of chromosomal region 10q23-q25 in prostate cancer
21. Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer
22. Distinct deleted regions on chromosome segment 16q23-24 associated with metastases in prostate cancer
23. Localization of potential tumor suppressor loci to a <2 Mb region on chromosome 17q in human prostate cancer
24. Allelic loss on 18q21 are associated with progression and metaastasis in human prostate cancer
25. Identification of genetic markers for prostatic cancer progression
26. Genetic changes in primary recurrent prostate cancer by comparative genomic hybridization
27. Genetic alterations in untreated metastases androgen-independent prostate cancer detected by comparative genomic hybridization
28. Genetic alterations in hormone-refractory recurrent prostate carcinomas
29. Interphase cytogenetic analysis of solid tumors by non-isotopic DNA in situ hybridization
30. Fluorescence in situ hybridization evaluation of chromosome deletion patterns in prostate cancer
31. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays
32. Interphase cytogenetics of prostatic tumor progression: Specific chromosomal abnormalities are involved in metastasis to the bone
33. Aneuploidy aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers for poor prognosis in prostate cancer
34. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma
35. Evaluation of the digital rectal examination as a screening test for prostate cancer: Rotterdam section of the European Randomized Study of Screening for Prostate Cancer
36. Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer
37. Histologic grading of prostate cancer
38. Universal linkage system (ULS): An improved method for labeling archival DNA for comparative genomic hybridization
39. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors
40. Detection of chromosomal gains losses in comparative genomic hybridization analysis bases on standard reference intervals
41. Prostate cancer is highly predictable: A prognostic equation based on all morphological variables in radical prostatectomy specimens
42. Mechanisms of tumor progression
43. Allelic loss on chromosome 8p12-p21 in microdissected prostatic intraepithelial neoplasia
44. Allelic loss in locally metastatic, multisampled prostate cancer
45. Minimal sizes of deletions detected by comparative genomic hybridization
46. Interphase cytogenetics of prostatic adenocarcinomas and precursor lesions: Analysis of 25 radical prostatectomies and 17 adjacent prostatic intraepithelial neoplasias
47. 8p22 loss concurrent with 8c gain is associated with poor outcome in prostate cancer
48. Isochromosome 8q formation is associated with 8p loss of heterozygosity in a prostate cancer cell line